May 19, 2022
Article
Generics are now available for the two drugs: Vimpat and Combigan.
May 19, 2022
Article
The FDA has changed how often AcelRx Pharmaceuticals is required to audit healthcare settings that administer Dsuvia, which is a synthetic opioid.
May 18, 2022
Article
Aetna has made available four specialty drugs that were approved early in 2022 through prior authorization. These include a biosimilar, a CAR-T immunotherapy, and therapies for macular degeneration and a rare auto-immune disease.
May 18, 2022
Article
While regulatory flexibility is important for drugs for rare diseases, investigators are concerned the trend toward surrogate endpoints decreases confidence that new drugs can improve patient outcomes.
May 17, 2022
Article
FDA regulators said the data to support the EUA, which was submitted by a physician, is not sufficient to support the use of the antidepressant fluvoxamine for the treatment of patients with COVID-19.
May 16, 2022
Article
The role of health economic and real-world evidence has become, and will continue to be, an important aspect of healthcare decision-making.